Zura Bio (ZURA)
NASDAQ:ZURA
ZURA Stock Chart & Stats
$5.60
-$0.21(-8.71%)
At close: 4:00 PM EST
$5.60
-$0.21(-8.71%)
Day’s Range― - ―
52-Week Range$0.98 - $7.44
Previous CloseN/A
Volume136.30K
Average Volume (3M)553.49K
Market Cap
$536.08M
Enterprise Value$257.97M
Total Cash (Recent Filing)$109.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
May 07, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding94,880,710
10 Day Avg. Volume579,596
30 Day Avg. Volume553,488
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.45K
Enterprise Value/Ebitda-3.50
Forecast
1Y Price Target
$17.75Price Target Upside216.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dual-target BiologyAnalyst highlights that tibulizumab's dual-pathway design targeting BAFF and IL-17 may provide combined B-cell and inflammatory control, potentially reducing the need for separate combination treatments.
External Clinical SupportAnalyst notes that external clinical evidence for IL-17 blockade in hidradenitis suppurativa and early signals for B-cell approaches support confidence in tibulizumab's potential to improve patient outcomes.
Feasible Registrational PathwayAnalyst observes that the targeted indications do not require extremely large registrational trials, making independent development more feasible and reducing reliance on external partners.
Bears Say
Binary Clinical Trial RiskAnalyst warns that the investment case depends heavily on successful clinical trial results, and negative outcomes would materially weaken investor confidence.
Financing And Execution RiskAnalyst notes that an adverse clinical readout could force reprioritization, increase financing needs, or delay other pipeline programs, eroding the company's strategic flexibility.
Single-asset ConcentrationAnalyst cautions that heavy reliance on a single lead program amplifies downside exposure if tibulizumab faces efficacy, safety, or enrollment setbacks.
Zura Bio News
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $0.98 and its highest was $7.44 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $536.08M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is May 07, 2026 which is in 26 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Mar 19, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.196 by -$0.294.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.17.
How many shares outstanding does Zura Bio have?
Zura Bio has 94,880,710 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.196. Following the earnings report the stock price went down -10.131%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in ZURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zura Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.75 (216.96% Upside)
$17.75 (216.96% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
359.01%
12-Months-Change
Fundamentals
Return on Equity
-83.86%
Trailing 12-Months
Asset Growth
-36.53%
Trailing 12-Months
Company Description
Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
ZURA Stock 12 Month Forecast
Average Price Target
$17.75
▲(216.96% Upside)
Technical Analysis
Ownership Overview
12.82% Insiders
1.59% Mutual Funds
35.62% Other Institutional Investors
49.31% Public Companies and
Individual Investors